Acute graft-versus-host disease (GVHD) is a common immune complication that can occur
after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major …

Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an immune checkpoint molecule that is mainly
expressed on activated T cells and regulatory T (Treg) cells that inhibits T-cell activation and …

Background Responses to conventional donor lymphocyte infusion for postallogeneic
hematopoietic cell transplantation (HCT) relapse are typically poor. Natural killer (NK) cell …

The key immunologic signatures associated with clinical outcomes after posttransplant
cyclophosphamide (PTCy)-based HLA-haploidentical (haplo) and HLA-matched bone …

PURPOSE Graft-versus-host disease (GVHD) causes morbidity and mortality following
allogeneic hematopoietic cell transplantation. Naive T cells (TN) cause severe GVHD in …

The use of HLA-mismatched donors could enable more patients with ethnically diverse
backgrounds to receive allogeneic hematopoietic cell transplantation (HCT) in the United …

Stem cell transplant (SCT) outcomes in high-risk and relapsed/refractory (R/R) pediatric
acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have been historically …

Advances in conditioning, graft-versus-host disease (GVHD) prophylaxis and antimicrobial
prophylaxis have improved the safety of allogeneic hematopoietic cell transplantation (HCT) …

Advances in understanding the ways in which the immune system fails to control tumor
growth or prevent autoimmunity have led to the development of powerful therapeutic …

The sole curative therapy for myelodysplastic syndrome (MDS) is allogeneic hematopoietic
cell transplantation (HCT). Here this therapeutic modality is reviewed and critically evaluated …